Although at present the significance of these mutations in terms of response to target therapies is not known, the ALK mutation c.3824G>A (p.R1275Q), albeit infrequent in lung cancer, is commonly found in neuroblastoma, where this mutation covers about one third of all ALK mutations, which affect about 8–9% of the cases (Tate et al., 2019). This evidence concerns the gene ALK and lung cancer.